Trade Gilead ^GILD

Western Financial Corp CA Takes $1.11 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B | Morningstar

Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration | Morningstar

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MOKAN Wealth Management Inc.

Unrivaled 2025: Ron Machen of WilmerHale

Kymera brings on Gilead as partner while Sanofi alters deal | BioWorld

61,815 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Spirepoint Private Client LLC

Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Asset Management One Co. Ltd.

Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel O'Day

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Oppenheimer & Co. Inc. Purchases 3,883 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Ewa LLC Acquires New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Stake Cut by Manning & Napier Advisors LLC

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Synergy Asset Management LLC

6,874 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Heartland Bank & Trust Co

Advisor Resource Council Invests $995,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Stake Cut by PFG Investments LLC

Avior Wealth Management LLC Sells 7,760 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

US FDA approves twice-a-year HIV shot that could end daily pills

Covea Finance Buys Shares of 30,500 Gilead Sciences, Inc. (NASDAQ:GILD)

Wealth Enhancement Advisory Services LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

USFDA okays Lenacapavir: Affordable, generic India-made drug key to boost global HIV prevention

Good Steward Wealth Advisors LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

FDA Approves First Twice-a-Year HIV Prevention Shot

Private Wealth Partners LLC Sells 3,050 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

US approves Gilead's twice-yearly injection to prevent HIV - The Economic Times

Oppenheimer Sticks to Their Buy Rating for Gilead Sciences (GILD) | Markets Insider

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

US approves Gilead's twice-yearly injection to prevent HIV - The Hindu

Sterling Investment Counsel LLC Acquires New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know… | Mint

Sowell Financial Services LLC Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Janney Montgomery Scott LLC Sells 58,538 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Lenacapavir or Yeztugo becomes first FDA approved HIV preventive drug given twice-yearly injection - India Today

US approves Gilead's twice-yearly shot for HIV prevention | South China Morning Post

BMO Capital Keeps Their Buy Rating on Gilead Sciences (GILD) | Markets Insider

FDA Approves Gilead's Yeztugo As First Twice-Yearly Injectable PrEP For HIV Prevention

Health Care Flat as Traders Hedge on Rates - Health Care Roundup | Morningstar

FDA Approves Twice-Yearly Shot for HIV Prevention | MedPage Today

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS Detroit

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS Colorado

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS Los Angeles

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News

Gilead wins FDA approval for twice-yearly HIV prevention jab

FDA approves the world's only twice-a-year shot to prevent HIV

FDA approves twice-a-year injection for HIV prevention | CNN

Bender Robert & Associates Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)

State of Alaska Department of Revenue Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

CWA Asset Management Group LLC Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Kingswood Wealth Advisors LLC Has $3.98 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Roman Butler Fullerton & Co. Acquires 2,654 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Wolf Group Capital Advisors Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Grove Bank & Trust Buys 3,572 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $275,425.00 in Stock

Johanna Mercier Sells 3,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Grimes & Company Inc. Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cyndeo Wealth Partners LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Brown Miller Wealth Management LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Position Lifted by Sound Income Strategies LLC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD | Morningstar

Mn Services Vermogensbeheer B.V. Sells 35,700 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Exchange Traded Concepts LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Atlas Private Wealth Advisors Sells 3,707 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Gilead Sciences, Inc. (NASDAQ:GILD) is Verity & Verity LLC's Largest Position

Thomasville National Bank Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Simon Quick Advisors LLC Raises Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Fifth Third Bancorp Acquires 76,007 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fort Washington Investment Advisors Inc. OH

Bellecapital International Ltd. Sells 3,415 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Davis Investment Partners LLC Invests $533,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Sapient Capital LLC Has $20.77 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Simplicity Wealth LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Visionary Horizons LLC

22,137 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Transform Wealth LLC

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by USA Financial Formulas

CX Institutional Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Monarch Capital Management Inc. Sells 2,390 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Gilead: FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182 | Morningstar

Gilead Sciences (NASDAQ:GILD) Shares Gap Down - Time to Sell?

Cantor Fitzgerald Predicts Gilead Sciences FY2026 Earnings

Atwood & Palmer Inc. Has $38.67 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Handelsbanken Fonder AB

Should You Be Impressed By Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE? - Simply Wall St News

FDA Halts Gilead's HIV Trials Over Safety Signal

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MADDEN SECURITIES Corp

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cardinal Capital Management Inc.

Tounjian Advisory Partners LLC Invests $424,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Farther Finance Advisors LLC

CHICAGO TRUST Co NA Invests $258,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

OLD National Bancorp IN Sells 5,365 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Best Stocks: Three healthcare names to ponder including a biotech back to levels not seen in a decade

Range Financial Group LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)